The recent layoffs signal a significant shift within BioMarin Pharmaceutical, as the company undergoes an "organizational redesign" amidst ongoing financial pressures related to its hemophilia drug Roctavian.
According to the WARN document, the layoffs predominantly affect California workers, with San Rafael and Novato offices experiencing the highest number of layoffs, impacting many management-level employees.
In the SEC filing, BioMarin indicated that some of the laid-off employees might have the opportunity to find "alternative positions" within the company, although the layoffs are classified as permanent.
Collection
[
|
...
]